Cargando…
Diversity of immune checkpoints in cancer immunotherapy
Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macropha...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027905/ https://www.ncbi.nlm.nih.gov/pubmed/36960057 http://dx.doi.org/10.3389/fimmu.2023.1121285 |
_version_ | 1784909815726735360 |
---|---|
author | Guo, Zhangyan Zhang, Rui Yang, An-Gang Zheng, Guoxu |
author_facet | Guo, Zhangyan Zhang, Rui Yang, An-Gang Zheng, Guoxu |
author_sort | Guo, Zhangyan |
collection | PubMed |
description | Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macrophages and others. In this review, we discuss the checkpoint molecules with enhanced expression on these lymphocytes and their consequences on immune effector functions. Dissecting the diverse roles of immune checkpoints in different immune cells is crucial for a full understanding of immunotherapy using checkpoint inhibitors. |
format | Online Article Text |
id | pubmed-10027905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100279052023-03-22 Diversity of immune checkpoints in cancer immunotherapy Guo, Zhangyan Zhang, Rui Yang, An-Gang Zheng, Guoxu Front Immunol Immunology Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macrophages and others. In this review, we discuss the checkpoint molecules with enhanced expression on these lymphocytes and their consequences on immune effector functions. Dissecting the diverse roles of immune checkpoints in different immune cells is crucial for a full understanding of immunotherapy using checkpoint inhibitors. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10027905/ /pubmed/36960057 http://dx.doi.org/10.3389/fimmu.2023.1121285 Text en Copyright © 2023 Guo, Zhang, Yang and Zheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Guo, Zhangyan Zhang, Rui Yang, An-Gang Zheng, Guoxu Diversity of immune checkpoints in cancer immunotherapy |
title | Diversity of immune checkpoints in cancer immunotherapy |
title_full | Diversity of immune checkpoints in cancer immunotherapy |
title_fullStr | Diversity of immune checkpoints in cancer immunotherapy |
title_full_unstemmed | Diversity of immune checkpoints in cancer immunotherapy |
title_short | Diversity of immune checkpoints in cancer immunotherapy |
title_sort | diversity of immune checkpoints in cancer immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027905/ https://www.ncbi.nlm.nih.gov/pubmed/36960057 http://dx.doi.org/10.3389/fimmu.2023.1121285 |
work_keys_str_mv | AT guozhangyan diversityofimmunecheckpointsincancerimmunotherapy AT zhangrui diversityofimmunecheckpointsincancerimmunotherapy AT yangangang diversityofimmunecheckpointsincancerimmunotherapy AT zhengguoxu diversityofimmunecheckpointsincancerimmunotherapy |